Constipation Treatment Market Report 2026

The constipation treatment market size has grown strongly in recent years. It will grow from $12.71 billion in 2025 to $13.75 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to high prevalence of gastrointestinal disorders, sedentary lifestyle patterns, dietary fiber deficiency, reliance on traditional laxatives, aging population growth.

The constipation treatment market size is expected to see strong growth in the next few years. It will grow to $18.72 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to rising chronic constipation cases, increasing opioid usage, growing awareness of gut health, expansion of specialty gastroenterology care, improved access to novel therapeutics. Major trends in the forecast period include rising use of prescription therapies for chronic constipation, growing adoption of probiotics and gut health products, shift toward targeted mechanism-based drugs, increased focus on opioid-induced constipation management, expansion of online pharmacy distribution.

The increasing prevalence of gastrointestinal disorders is expected to support the growth of the constipation treatment market in the coming years. Gastrointestinal disorders, also known as digestive disorders, include a wide range of conditions that affect the digestive tract. Constipation is a frequent symptom associated with many gastrointestinal (GI) disorders. The rising occurrence of gastrointestinal conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) is driving demand for constipation treatments, as these disorders commonly coexist with constipation, increasing the need for targeted and effective therapies alongside growing disease awareness. For example, in January 2024, according to the American Cancer Society, a US-based nonprofit organization, around 26,890 new cases of stomach cancer were projected in the United States in 2024, including 16,160 cases in men and 10,730 cases in women. It was also estimated that this cancer type would result in approximately 10,880 deaths, comprising 6,490 men and 4,390 women. Therefore, the rising incidence of gastrointestinal disorders is contributing to the expansion of the constipation treatment market.

Companies operating in the constipation treatment market are increasingly focusing on the development of innovative solutions such as drug-free mechanical stimulation capsules, also known as vibrating capsules, to address growing demand for effective therapies that minimize side effects. This demand is driven by factors including an aging population, increased opioid usage, and patient preference for non-pharmacologic treatment options. A vibrating capsule is a swallowable, single-use oral device that contains a small vibration motor and battery enclosed within a medical-grade, excretable shell. It is designed to mechanically stimulate the colon at programmed intervals to trigger peristalsis, enabling predictable bowel movements without the systemic effects associated with laxatives or prescription prokinetic drugs. For instance, in May 2023, Vibrant Ltd., a US-based medical technology company, introduced Vibrant, a prescription-only vibrating capsule system approved by the US Food and Drug Administration (FDA) for adults with chronic idiopathic constipation who did not respond to laxative therapy. The system consists of a reusable activation pod and a single-use capsule containing a coin-sized vibration motor, an electronic control unit, and batteries housed within a two-piece shell. The activation pod programs the capsule to deliver short vibration cycles, approximately 190 cycles per hour with scheduled bursts and rest periods, specifically engineered to stimulate colonic contractions.

In March 2023, Ipsen, a France-based pharmaceutical company, acquired Albireo Pharma Inc. for an undisclosed amount. Through this acquisition, Ipsen strengthened its rare disease portfolio. Albireo Pharma Inc. is a US-based biotechnology company focused on developing treatments for chronic constipation.

Major companies operating in the constipation treatment market are Pfizer, Johnson & Johnson, AbbVie, Bayer, Sanofi, Fresenius Kabi, GlaxoSmithKline, Takeda Pharmaceutical Company Ltd, Bausch Health Companies Inc, Salix Pharmaceuticals Inc, Prestige Consumer Healthcare Inc, Ironwood Pharmaceuticals Inc, Cosmo Pharmaceuticals NV, Ferring Pharmaceuticals, Probi AB, 4D Pharma plc, Abbott Laboratories, Albireo Pharma Inc, Ardelyx Inc, Synergy Pharmaceuticals Inc, Astellas Pharma Inc, Allergan plc.

North America was the largest region in the constipation treatment market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the constipation treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the constipation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the constipation treatment market by increasing costs of imported active pharmaceutical ingredients, specialty drugs, excipients, and packaging materials. Pharmaceutical manufacturers and hospital pharmacies in North America and Europe are most affected due to dependence on imported APIs, while Asia-Pacific experiences higher formulation input costs. These tariffs are raising drug prices. However, they are also supporting domestic drug manufacturing, generic drug development, and stronger regional pharmaceutical supply chains.

The constipation treatment market research report is one of a series of new reports that provides constipation treatment market statistics, including constipation treatment industry global market size, regional shares, competitors with a constipation treatment market share, detailed constipation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the constipation treatment industry. This constipation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Constipation treatment refers to the various approaches and measures used to relieve and manage the condition, which is characterized by infrequent or difficult bowel movements and often involves hard or dry stools. It is applied to evaluate the rectum and lower, or sigmoid, colon and to manage constipation.

The primary therapeutic types for constipation treatment include laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C (guanylate cyclase-C) agonists, and others. Laxatives are substances that promote the passage of intestinal waste in humans and are used in constipation treatment to enhance stool volume, frequency, and bowel motility. These therapies are used to treat conditions such as chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC) and are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The constipation treatment market consists of sales of polyethylene glycol, bisacodyl, tegaserod, lubiprostone, and senna. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.